Jeffrey A. Lieberman, M.D.

Dr Kantrowitz and Colleagues Reply

October 26, 2016

Joshua T. Kantrowitz, Alice Medalia, Richard S. E. Keefe, et al

Cognitive Remediation and Lurasidone in Schizophrenia

June 22, 2016

What is the best cognitive remediation method to use as an adjunct with lurasidone to help your patients with schizophrenia? These researchers compared auditory processing cognitive remediation against videogames....

Joshua T. Kantrowitz, Zafar Sharif, Alice Medalia, et al

Original Research

Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia

September 21, 2010

Donald E. Addington, Somaia Mohamed, Robert A. Rosenheck, et al

Original Research

Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia

August 10, 2010

Stanley N. Caroff, Vicki G. Davis, Del D. Miller, et al

Original Research

Comorbid Somatic Illnesses in Patients With Severe Mental Disorders: Clinical, Policy, and Research Challenges

March 18, 2008

W. Wolfgang Fleischhacker, Marcelo Cetkovich-Bakmas, Marc De Hert, et al

Original Research

Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder: A Randomized, Double-Blind, Flexible-Dose, Multicenter Study

January 15, 2008

Diana O. Perkins, Hongbin Gu, Peter J. Weiden, et al

Educational Activity

Comparing Safety and Tolerability of Antipsychotic Treatment

March 15, 2007

John W. Newcomer, Jeffrey A. Lieberman

Educational Activity

Effectiveness of Antipsychotic Drugs in Patients With Chronic Schizophrenia: Efficacy, Safety, and Cost Outcomes of CATIE and Other Trials

February 15, 2007

Jeffrey A. Lieberman

Educational Activity

Cost-Effectiveness Measures, Methods, and Policy Implications From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia

February 15, 2007

Robert A. Rosenheck, Jeffrey A. Lieberman

Academic Highlights

Practical Applications of Recent Antipsychotic Effectiveness Data.

January 15, 2007

Jeffrey A. Lieberman, Phillip D. Harvey, John W. Newcomer, et al

Educational Activity

Neurobiology and the Natural History of Schizophrenia

October 1, 2006

Jeffrey A. Lieberman

Educational Activity

Neuroprotection in Schizophrenia

September 15, 2006

L. Fredrik Jarskog, Jeffrey A. Lieberman

Dr Kantrowitz and Colleagues Reply

Cognitive Remediation and Lurasidone in Schizophrenia

Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia

Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia

Comorbid Somatic Illnesses in Patients With Severe Mental Disorders: Clinical, Policy, and Research Challenges

Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder: A Randomized, Double-Blind, Flexible-Dose, Multicenter Study

Comparing Safety and Tolerability of Antipsychotic Treatment

Effectiveness of Antipsychotic Drugs in Patients With Chronic Schizophrenia: Efficacy, Safety, and Cost Outcomes of CATIE and Other Trials

Cost-Effectiveness Measures, Methods, and Policy Implications From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia

Practical Applications of Recent Antipsychotic Effectiveness Data.

Neurobiology and the Natural History of Schizophrenia

Neuroprotection in Schizophrenia

ELSEWHERE:

FOLLOW US:

Jeffrey A. Lieberman, M.D.

Dr Kantrowitz and Colleagues Reply

Cognitive Remediation and Lurasidone in Schizophrenia

Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia

Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia

Comorbid Somatic Illnesses in Patients With Severe Mental Disorders: Clinical, Policy, and Research Challenges

Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder: A Randomized, Double-Blind, Flexible-Dose, Multicenter Study

Comparing Safety and Tolerability of Antipsychotic Treatment

Effectiveness of Antipsychotic Drugs in Patients With Chronic Schizophrenia: Efficacy, Safety, and Cost Outcomes of CATIE and Other Trials

Cost-Effectiveness Measures, Methods, and Policy Implications From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia

Practical Applications of Recent Antipsychotic Effectiveness Data.

Neurobiology and the Natural History of Schizophrenia

Neuroprotection in Schizophrenia

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles